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Tumor microenvironments (TMEs) are composed of cancer cells, fibroblasts, extracellular matrix, microvessels,
and endothelial cells. Two prolyl endopeptidases, fibroblast activation protein (FAP) and prolyl oligopeptidase
(POP), are commonly overexpressed by epithelial-derived malignancies, with the specificity of FAP expression by
cancer stromal fibroblasts suggesting FAP as a possible therapeutic target. Despite overexpression in most
cancers and having a role in angiogenesis, inhibition of POP activity has received little attention as an approach to
quench tumor growth. We developed two specific and highly effective pseudopeptide inhibitors, M83, which
inhibits FAP and POP proteinase activities, and J94, which inhibits only POP. Both suppressed human colon
cancer xenograft growth N90% in mice. By immunohistochemical stains, M83- and J94-treated tumors had fewer
microvessels, and apoptotic areas were apparent in both. In response to M83, but not J94, disordered collagen
accumulations were observed. Neither M83- nor J94-treated mice manifested changes in behavior, weight, or
gastrointestinal function. Tumor growth suppression was more extensive than noted with recently reported efforts
by others to inhibit FAP proteinase function or reduce FAP expression. Diminished angiogenesis and the
accompanying profound reduction in tumor growth suggest that inhibition of either FAP or POP may offer new
therapeutic approaches that directly target TMEs.
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Tumor microenvironments (TMEs) as small as 1 to 2 mm3 contain
parenchymal-derived cancer cells within stroma that is composed of
activated fibroblasts, developing microvasculature, and extracellular
matrix (ECM); stroma may account for ~90% of tumor weight [1,2].
Fibroblast activation protein (FAP), a type II integral membrane
protein and prolyl-specific serine proteinase, is overexpressed on cell
membranes of fibroblasts in more than 90% of epithelial cell–derived
malignancies, i.e., lung, breast, colon, and so on [3,4]. FAP is rarely
found on adult normal tissues and is essentially absent on benign
tumors, features that make it an attractive diagnostic and therapeutic
target [5–10]. It is believed that 1) FAP engages in proteolysis of
ECM during tissue invasion [11–15], 2) FAP-expressing cells appear
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expressing cells support angiogenesis [9,10,23–26]. Efforts to limit
FAP activities that might enhance tumor growth have focused on
inhibiting its proteolytic properties [5,24,27] or blocking putative FAP+
cell–induced immunotolerance of growing cancer [16,17,20–22].
Commanding less attention has been another prolyl oligopeptidase
(POP) normally found in many tissues but commonly overexpressed
along with the ubiquitous protein thymosin β4 in a number of
malignancies [28–36]. Following partial cleavage of Tβ4 by an
unknown enzyme, its degraded form is digested further by POP to
yield the potent angiogenic peptide, Ac-SDKP [37,38]. POP
proteinase activity clearly has a role in angiogenesis [38–41], but
unlike FAP, it resides on cells throughout the tumor and not just on
stroma. While inhibition of POP proteolytic activity is reported to
arrest the growth of gastric cancer cells in culture [42], in vivo studies
of POP inhibition in tumor models are lacking. The individual
contribution of either POP or FAP to tumor expansion is difficult to
decipher, given their overlapping proteolytic activities for cleaving Z-
Gly-Pro-AMC, succinyl-Gly-Pro-AMC, and similar non-specific
substrates; in addition, the lack of highly efficient aqueous soluble
specific inhibitors of FAP or POP adds to the problem.
Despite lacking specificity, PT-100 (valyl-proline boronic acid;
Val-boroPro) and PT-630 (glutamyl-proline boronic acid; Glu-
boroPro) have been used to study the effects of FAP proteinase
inhibition on cancer growth [24,43–47]. Both PT-100 and PT-630,
however, also inhibit dipeptidyl peptidase IV (DPPIV) and, to a lesser
extent, POP in purified solution. Moreover, PT-100 and PT-630 both
rapidly cyclize in physiologic media and lose inhibitory activity [48,49].
Narra et al. [45] and Santos et al. [24] showed that PT-630 inhibited
endogenous lung cancer growth in immunodeficient mice and in
syngeneic colon cancer grafts inmice. In both studies, inhibition of FAP
or DPPIV by PT-100 or PT-630 appeared to suppress tumor growth
[24,43,50]. Huang et al. [51,52] reported that human breast cancer
cells transfected with proteolytically inactive recombinant FAP, or
breast cancer cells transfected to express wild-type proteolytically active
FAP that is inhibitable by PT-630, still formed rapidly growing breast
tumors in severe combined immunodeficiency mice. As a consequence,
they suggested that FAP proteolytic activity has little or no impact on
cancer growth; however, since transfected cancer cells served as FAP+
cells instead of stromal fibroblasts as in human breast cancers, their
model differed from established biology of such cancers [51].
In a mouse syngeneic 4T1 mammary carcinoma model, when
short hairpin inhibitory RNA (shRNA) targeting FAP was injected
intratumorally and peritumorally, FAP expression was knocked down
by ~50%, tumor growth was reduced, angiogenesis was suppressed,
collagen accumulation increased within the tumor, and tumor
apoptosis was promoted; apparent side effects were not noted [53].
FAP gene silencing for 17 days did not induce paraneoplastic features
such as cachexia, anemia, and lethal bone toxicities that were noted
with tumor growth inhibition by immunologic depletion of FAP+
cells within TME [18–20]. Given the reduction in FAP protein, FAP
proteinase activity should also have been significantly reduced.
Interestingly, the FAP-knockdown results closely mirrored those
yielded by studies in which FAP proteinase activity was inhibited
[24,45]. The sum of studies to date clearly indicates the need for
more efficient and predictable FAP inhibition to determine whether
simply inhibiting FAP proteolytic activity will circumvent FAP+ cell
destruction and thereby avoid perturbing potential FAP+ cell
functions that might cause adverse constitutional effects. Moreover,the suggested therapeutic potential for targeted POP inhibition to
diminish angiogenesis and reduce tumor growth [40,54] has not been
explored as far as we are aware and deserves direct evaluation. To
examine these issues, we designed and synthesized a more stable,
specific, and soluble FAP and POP inhibitor that we termed M83 and
a highly specific, soluble inhibitor of POP only that we designated as
J94 [10,49].
We used the primary structure surrounding the scissile bond of the
only established physiologic substrate for FAP, namely, alpha2-
antiplasmin, as a template for designing M83 [49,55]; similarly, the
scissile bond region of POP substrates was used to design J94 [49,56].
Extensive characterization showed that both inhibitors possessed
similar features, i.e., excellent aqueous solubility at neutral pH, low
molecular weights [529 (M83) and 554 (J94)], absence of cyclization
in aqueous solution, and retention of inhibitory function after
prolonged exposure to human plasma. Both are charged and
hydrophilic, thereby minimizing intracellular entry; moreover, both
M83 and J94 have low nanomolar Ki values for inhibiting FAP or
POP or only POP, respectively. J94 does not inhibit FAP and neither
M83 nor J94 significantly inhibits DPPIV [49]. When on live cells
characteristic of TME, the membrane-associated form of either enzyme
can be rapidly and completely inhibited, suggesting easy accessibility to
the active site [10]. We now report analyses of substantial growth
suppression of human colon cancer xenografts by M83 or J94 in
immunodeficient mice without apparent adverse effects.
Methods
Cell Culture
HCT116, a human colon cancer cell line, and H441, a human
lung cancer cell line, were obtained from ATCC (Manassas, Virginia)
and grown as monolayer cultures in RPMI or Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum. Cells were
maintained in a humid 5% CO2 atmosphere at 37°C.
Drug Design and Synthesis
The FAP/POP dual inhibitor, M83, was synthesized in two steps
as previously reported [49]. Briefly, a structure consisting of acetyl-
Arg(Pbf)-peg-D-Ala, based on the sequence surrounding the P1-P1′
scissile bond in Met-α2AP, where peg is defined as 8-amino-3,6-
dioxaoctanoic acid and Pbf represents N G-2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl, was synthesized and
purified. The second step of the synthesis was linking this protected
peptide-like construct to L-boroPro pinanediol ester and subse-
quently purifying the protected product. Finally, the pinanediol and
Pbf groups were chemically removed and M83 was purified by
reversed-phase HPLC.
The POP specific inhibitor, J94, was prepared using the equivalent
strategy as for M83. The design of the precursive molecule was based
on the reported sequence N-terminal to the scissile bond of optimal
peptide substrates determined for POP [56]. The protected tripeptide
acetyl-Lys(Boc)-Leu-Arg(Pbf)-OH was synthesized and purified, where
Boc representsN-tert-butyloxycarbonyl. The second step was identical
to that for M83, where the precursor peptide was linked to L-boroPro
pinanediol ester and then HPLC purified.
Animals
Five- to six-week-oldmale athymic nudeFoxn1numicewere purchased
from Harlan Laboratories (Houston, Texas). Animals were allowed to
acclimate for ~5 days before any procedures. All animal protocols used in
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Committee of the University of Oklahoma Health Sciences Center.
Tumor Models
HCT116 colon cancer cells (2.5 × 106) or H441 lung cancer cells
(2 × 106) were suspended in Matrigel (BD Biosciences, San Jose,
California) and injected subcutaneously with a 28G needle on the
dorsal side of each thigh of Foxn1nu mice. After 10 days, the mice
were randomly assigned to treatment groups. For lung cancer
xenografts, animals were treated with 50 μl of saline (vehicle control)
through intraperitoneal (i.p.) injection daily in the lower left
abdominal quadrant or with 26.5 μg of M83 in saline. For the first
experiment with colon cancer xenografts, animals were treated with
50 μl of saline through i.p. injection daily, 50 μg of M83, or 50 μg of
J94 in saline. For the second colon cancer xenograft study, the
animals were treated with 50 μl of saline through i.p. injection daily,
50 μg of M83, or 100 μg of M83 in saline. Mouse weight and tumor
growth were monitored about every 3 days. Tumor volume,
indicative of tumor growth, was determined by measuring two
perpendicular diameters with calipers and converting to cm3 using
the following formula: volume = (width)2 × length/2. Activity, eating,
and bowel function were monitored daily. Experiments were
performed with six animals per treatment group for lung cancer, six
animals per group for the first colon cancer experiment, and three
animals per group for the second experiment. Mice were treated for
28 days, after which they were killed. Tumors and selected organs
were harvested and placed in 5% buffered formalin or 4%
paraformaldehyde or flash frozen in liquid nitrogen for future
pathologic or biochemical analyses. FAP activity in control and M83-
treated tumors was determined on membranes prepared according to
the manufacturer’s instructions (Mem-Per Plus, Pierce) using the
fluorescent substrate acetyl-Arg-AEEA-Gly-Pro-AMC [10]. Signifi-
cance of tumor volume and FAP activity results were analyzed by two-
sample t test using the statistical package contained within Origin 9.1
(P b .05 was considered significant).
Histologic and Immunohistochemical Analyses
Tumors and selected organs were harvested and paraffin embedded
after fixationwith 5%buffered formalin. Tissues were cut in 4-μm slices
and stained with hematoxylin and eosin for histologic examination.
For immunohistochemistry (IHC), tissue samples were fixed by
immersion in 4% paraformaldehyde in phosphate-buffered saline (PBS)
overnight at 4°C, followed by several buffer washes. The samples were
then cryoprotectedwith a solution of 15% sucrose in PBS and embedded
in Optimal Cutting Temperature compound. Ten-micrometer cryosec-
tions were prepared using a MicromHM500 E microtome cryostat and
washed with PBS at 20°C, and free aldehyde groups were quenched with
0.1 M glycine in PBS (15 minutes). The tissue samples were
permeabilized with 0.01% saponin in PBS (PBS/SAP; 10 minutes at
20°C) and incubated in 3%BSA in PBS/SAP (1 hour at 20°C). Saponin
was kept in all incubation buffers throughout the staining procedure to
ensure a proper penetration of the antibodies.
The tissue sections were placed in mixtures of monoclonal antibodies
(mAbs) and polyclonal IgGs for 1 hour at 20°C or overnight at 4°C. The
antibodies were rabbit anti–FAP-1 IgG (10 μg/ml; Sigma, St. Louis,
Missouri; SAB4500839), rat anti-mouse CD31 IgG (1.5 μg/ml; BD
Pharmingen, San Jose, California; 550274), mouse anti–single-stranded
DNA (anti-ssDNA) IgM (10 μg/ml; Millipore, Billerica, Massachusetts;
MAB3299), and goat anti-POP/PREP IgG (5 μg/ml; R&D Systems,Minneapolis, Minnesotta; AF4308). Then, the samples were washed
3 × 10 minutes in PBS/SAP and incubated for 1 hour at 20°C with
combinations of appropriate detection antibodies conjugated with
fluorescein isothiocyanate or Cy3 diluted 1:100 in 1% BSA in PBS/SAP.
Secondary antibodies used were donkey anti-rabbit Cy3 (Jackson
ImmunoResearch, West Grove, Pennsylvania; 711-165-152), donkey
anti-rat fluorescein isothiocyanate (Jackson ImmunoResearch; 712-095-
153), donkey anti-goat Cy3 (Jackson ImmunoResearch; 705-165-147),
and F(ab) donkey anti-mouse Cy3 (Jackson ImmunoResearch; 715-165-
003). All secondary antibodies were used at 15 μg/ml. After washing as
above, the sections were mounted between glass slides and coverslips
using VECTASHIELD HardSet Mounting Medium (Vector Laborato-
ries, Burlingame, CA) containing TO-PRO-3 iodine (1 μM; Molecular
Probes, Eugene, OR) as a nuclear counterstain. In case of mouse mAbs,
the tissue sections were incubated with unconjugated Fab fragment anti-
mouse IgG (at 0.1 mg/ml) for 1 hour at room temperature to block the
endogenous mouse IgG. As detection antibodies, F(ab) monomeric
secondary antibodies were used.
As negative controls for polyclonal antibody staining, the primary
antibodies were replaced with equivalent amounts of rabbit or sheep
nonimmune serum. Monoclonal antibody against digoxigenin, a
hapten antigen that occurs only in plants, was used as control for
mAb staining. Specimens were examined by epifluorescence confocal
imaging using a Nikon C1 confocal laser-scanning unit equipped with a
three-laser launcher (488, 543, and 633 nm emission lines) installed on
an Eclipse TE200-U inverted microscope (Nikon, Melville, NY).
Images were taken with a ×20 plan achromat objective (NA 0.46).
Image collection parameters (neutral density filters, pinhole, and
detector gains) were kept constant during image acquisition.
For the collagen staining, tissue samples were fixed by immersion
in 4% paraformaldehyde in PBS overnight at 4°C, followed by several
buffer washes. The samples were then cryoprotected with a solution
of 15% sucrose in PBS and embedded in Optimal Cutting
Temperature compound. Ten cryosections were obtained using a
Microm HM500 E microtome and then stained with 0.1% sirius red
F3B (Sigma) in saturated picric acid (Sigma).
Apoptosis was quantified by integration of the relative area stained
by the anti-ssDNA antibody compared to the total tissue area for
randomly selected slides from twelve different tumors, four from each
M83 and J94-treated mice and four from saline-treated mice. The
areas were determined using ImageJ software [57].
Immunoblot Analysis
Tumors were flash frozen and stored in liquid nitrogen before
being processed for immunoblot analysis. At the time of assay, tumors
were pulverized in a mortar and pestle under liquid nitrogen,
weighed, and solubilized in 2× sodium dodecyl sulfate (SDS) sample
buffer. Samples were electrophoresed under reducing conditions on
4% to 12% Bis-Tris SDS–polyacrylamide gel electrophoresis (PAGE)
gels (Invitrogen, Grand Island, New York) and transferred to
nitrocellulose for Western blot analysis. After blocking with 3%
BSA/TBS-Tween, blots were incubated with 0.5 μg/ml rabbit anti-
FAP (Sigma) or 0.2 μg/ml goat anti-POP (R&D Systems; #AF4308),
all in 3% BSA/TBS-Tween, and then washed and incubated with
either 1:105,000 goat anti-rabbit HRP (Thermo Fisher, Carlsbad,
California; #31460) or 1:100,000 rabbit anti-goat HRP (R&D
Systems; #HAF017). Blots were washed extensively and then
developed with ECL-Plus (Thermo Fisher) and were visualized on
RPI blue radiographic film (Amersham, Pittsburgh, Pennsylvania).
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Western blot analysis, tumors were pulverized as above and then
solubilized in immunoprecipitation buffer [1% Triton/150mMNaCl/
10 mM Tris, pH 7.5/1 mM EDTA/1 mM EGTA/0.5% NP-40/10%
sucrose with cOmplete ULTRA protease inhibitor cocktail (Roche,
Indianapolis, Indiana)]. Lysates were centrifuged to remove detergent-
insoluble debris. For FAP, 20 μg/ml polyclonal sheep anti-FAP (R&D
Systems), or for POP, 20 μg/ml polyclonal goat anti-POP (R&D
Systems), was added and allowed to bind overnight at 4°C. Then, 25 μl
of 75% slurry of Protein A/G agarose beads (Thermo Fisher; #20421)
in TBSwere added and incubated for 3 hours at 4°C. Protein A/G beads
were spun down, washed three times with immunoprecipitation buffer,
resuspended in loading buffer, and boiled for 5 minutes; the beads were
removed by centrifugation and a portion of the supernatant was
electrophoresed under reducing conditions on 4% to 12% Bis-Tris
SDS-PAGE gels and then Coomassie stained. To confirm the presence
of FAP or POP, the regions of each lane corresponding to the molecular
weight of FAP or POP were excised and the proteins within each gel
slice were reduced with tris[2-carboxyethyl]phosphine, then alkylated
with iodoacetamide, and digested with trypsin as described by the
In-Gel Tryptic Digestion Kit protocol (Thermo Fisher). Each trypsin
digest sample was analyzed by HPLC–tandem mass spectrometry
(MS/MS) on a nanoscale DionexUltiMate 3000HPLC equipped with
an Acclaim PepMap C18 column (75 μm internal diameter × 15 cm
length with 3-μm particles) connected to an AB-Sciex QSTAR Elite
mass spectrometer. The peptide molecular weights and MS/MS
fragment ion spectra observed for each peptide were used to query an
Naitonal Center for Biotechnology Information (NCBI) comprehen-
sive non-identical human protein database (February 2012) loaded on
an in-house MASCOT database server (version 2.4).
Results
As previously published by us [49,55], M83 and J94 were each
assessed for the ability to inhibit activities of FAP and POP as
produced by cultures of cells typically within the TME [10]. Figure 1
shows the molecular design of each inhibitor. For M83, the arginyl
group has been shown by us to add binding specificity and aqueous
solubility, while the acetyl moiety obviates cleavage by dipeptidases.
The insertion of a polyethylene string likewise adds to solubility and
increases the length of the inhibitor to position the arginyl for
maximal binding; importantly, the additional length eliminates the
risk of cyclization as occurs with PT-100 and PT-630 [48,49]. The D-
alanyl residue fulfills the Gly requirement of the -Gly-Pro- motif of
the scissile bond–containing peptide in which the P2 group is small,
neutral, and essentially unreactive when binding within the FAPFigure 1. FAP and POP inhibitors. (A) M83, FAP, and POP inhibitor s
boronic acid (MW = 529.4). (B) J94, POP-specific inhibitor structure:active site [55] since the D-alanyl side chain projects into the aqueous
environment and away from the restricted space of the S2 pocket. The
structure of J94 inhibitor has acetyl attached to the N-terminal lysyl
residue, again for protection from dipeptidases. Leucine serves as the
requisite hydrophobic residue in P3 position, with positively charged
residues in P2 and P4 to enhance binding in the POP active site [56,58];
lysine in particular was selected for P4 since FAP showed essentially no
tolerance for P4 -lysyl-containing substrates [55], thereby eliminating
FAP inhibition by J94. The P1 -prolyl- is essential for conjugation of the
boronic acid warhead that directly interacts with the active site serine of
both FAP and POP. We previously showed that M83 has a Ki of
5.7 nM for FAP and 7.4 nM for POP, while J94 totally inhibits POP at
100 nM and does not inhibit FAP or DPPIV even at 10 μM, thus
providing specificity and equivalent efficiency [49].
Figure 2A shows that M83 inhibitor given as a daily 26.5 μg i.p.
dose very effectively suppressed the growth of human lung cancer
H441 xenografts in Foxn1nu mice, essentially halting growth of
visible, palpable ~0.04 cm3 tumors; all mice, untreated or treated,
remained alive, and none in the treated group showed signs of toxicity
over the entire 28-day treatment period; tumors in the untreated
group grew to an average volume of ~1.4 cm3 by 28 days at which
time the mice were killed. We next assessed treatment with either
M83 or J94 in mice with HCT116 human colon cancer xenografts.
Each treated mouse was given M83 or J94 inhibitor as a daily i.p. dose
of 50 μg when the tumors had grown to ~0.06 cm3. Tumors in
untreated mice attained a volume of ~3 cm3 by the end of the 28-day
period, and the mice were killed. As shown in Figure 2B, at treatment
doses of 50 μg/day, the M83 and J94 inhibitors each gave about the
same extent of tumor suppression over the 28-day treatment course.
Although impressive, the tumor growth curve for either inhibitor still
indicated continued expansion, and therefore, we repeated this
experiment with M83 and compared daily i.p. doses of 50 μg versus
100 μg to see if the increased dose caused more tumor suppression.
Indeed, it was evident that a greater limiting effect on tumor growth
occurred at 100 μg of M83 per day, with one tumor becoming no
longer palpable and another was barely evident; the growth of the
remainder were all significantly reduced. Figure 3A shows that the
individual tumor growth patterns for the 12 HCT116 human colon
cancer xenografts were remarkably similar for all six untreated mice,
with each growth curve showing two major inflections of accelerated
growth. In control mice, the first came about 7 days after beginning
saline i.p. injections, while the second growth burst occurred about
day 18; only 1 of the 12 control tumors showed a modest decline in
tumor volume, which occurred around day 24. By day 28, all but one
tumor had achieved a maximum volume that ranged from 2.2 totructure: acetyl-arginyl-8-amino-3,6-dioxaoctanoyl-D-alanyl-L-proline
acetyl-lysyl-leucyl-arginyl proline boronic acid (MW = 554.5).
Figure 2. Growth of human xenografts in Foxn1nu mice. Treatment
was initiated as i.p. drug injectionswhen tumors reached~0.060cm3
in size. Tumor volumes were measured over the course of 28 days of
treatment. (A) Human H441 lung cancer cell xenograft growth.
Treatment consisted of 50-μl saline injections (●) or M83, 26.5 μg in
50 μl of saline (○) per day. *The M83-treated group is statistically
different than the saline treatment for days 10 to 28 (P b .001).
(B)Humancolon cancerHCT116 xenograft growth.Micewere treated
with 50μl of saline (●) orM83 (▲), or J94 (■), 50μg in 50μl of saline per
day. **Both the M83 and J94 treatment groups are statistically
different than the saline-treated group for days 10 to 28 (P b .001).
(C)Humancolon cancerHCT116 xenograft growth.Micewere treated
with 50 μl of saline (●), M83, 50 μg in 50 μl of saline (▲), or M83,
100μg in 50μl of saline (■). ***BothM83 treatment groups, 50 μg and
100 μg, are statistically different than the saline group from days 18 to
28 (P b .02 and P b .003).
Figure 3. Human HCT116 colon cancer xenograft growth in
Foxn1nu mice. The growth of individual tumors was plotted over
the course of the 28-day treatment period. Treatment was initiated
as i.p. drug injections when tumors reached ~0.060 cm3 in size.
(A) Tumor growth in control mice treated with daily 50-μl saline
injection. (B) Tumor growth curves for mice treated with M83,
50 μg in 50 μl of saline daily.
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showing very substantial growth suppression, so that after 28 days,
residual tumor volumes ranged between 0.25 and 1.6 cm3 (~67-89%
tumor volume reduction relative to untreated tumors). At 20 days,
most of the treated tumors resumed slow growth, but between days
24 and 28, about half again began showing significant declines in
tumor volume that lasted through 28 days of treatment.Figure 4A to C show the xenograft implantation sites in mice given
daily i.p. injections of saline control, 50 μg of M83, and 100 μg of
M83, respectively, for 28 days. By the time untreated control mice
were killed at 28 days, the skin overlying untreated tumors was
inflamed (see Figure 4A) and the tumors were clearly beginning to
interfere with mobility. Figure 4B shows a typical response of a
xenograft tumor on a mouse treated with a daily dose of 50 μg of M83
for 28 days; the marked, progressive reduction in growth of such
tumors is clearly evident in Figure 2C. At the end of the treatment
period, these tumors usually showed obviously cratered, necrotic
centers (6 of 12) with edges that were neither inflamed nor sensitive to
moderate pressure. In one mouse receiving 100 μg/day M83
(Figure 4C), one tumor showed complete growth suppression and
disappeared entirely, while the residual of another tumor on the same
mouse was barely detectable at 28 days. Tumors from untreated mice
Figure 4. Images of left hindquarters of Foxn1numice with HCT116
colon cancer xenografts after 28 days of treatment with daily i.p.
injections of (A) saline, (B) 50 μg of M83, or (C) 100 μg of M83. The
excised tumors are shown below panels A and B. The saline-
treated mouse had a tumor weight of 1.95 g, while the mouse
treated with 50 μg of M83 had a tumor weight of 0.26 g. Of the six
tumors in the 100 μg M83 treatment group, one tumor was
completely suppressed (C), a second tumor was barely detectable,
and the remaining four tumors were significantly reduced in size.
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immunoprecipitated from tumor homogenate. Western immunoblot
analysis of each immunoprecipitate was performed and protein band
identities were confirmed by amino acid sequence determinations.
Our sequence results in Figure 5A and B directly confirm that mouse
and human FAPs are highly conserved and closely homologous. Since
the amino acid sequences of human and mouse FAPs are 93%
identical, the inhibitory efficiency we previously established for M83
toward human FAP should be closely similar, if not identical, for
mouse FAP; the inhibitory properties of J94 toward POP produced
by human colon cancer xenografts should be about the same as what
we have shown in purified solutions [49] and tissue culture [10].
Identifications of tryptic peptides of FAP derived from the HCT116
colon cancer indicate that the xenograft stroma is clearly derived from
the host, since no peptides unique to human FAP were observed. The
homology observed for POP between human and mouse forms,
although very significant, was not at the level of that for FAP. Amino
acid sequence determination on tryptic peptides of POP from extracts
of excised HCT116 xenografts established that tumor-associated
POP originated from human cancer cells. Interestingly, by
immunoblot analysis (Figure 5C and D), FAP and POP were each
present in about the same amount per weight of tumor from both
untreated and M83-treated mice, which raises skepticism about
whether the mere presence of FAP protein causes immune tolerance
in an already immunodeficient mouse and allows further growth of
HCT116 tumors, particularly since host-derived stromal fibroblasts
growing into the xenograft tumor could easily produce proteolytically
active FAP. Our results show that tumor growth is suppressed in
response to inhibition of FAP or POP proteolytic activity, thus
intimating that these two proteinase functions are critical for tumor
growth. With respect to POP, thymosin β4 peptides seem likely
substrates, given the apparent role of their derivatives in angiogenesis
[29–41]. Left open, however, is what substrate(s) might be involved,especially for cleavage by FAP, and this prompts conjectures about
whether FAP cleavage of minimally degraded or denatured ECM
proteins might yield peptides with unique biologic properties that
might participate in pro-tumorigenic cell signaling, or whether FAP
proteolytic function might be critical in pathways that promote
immune tolerance of tumor growth, but if inhibited, immune
intolerance is restored and growth becomes diminished. In the
present work, tumors from five control mice and five M83-treated
mice were analyzed for FAP proteolytic activity. In the M83-treated
animals, FAP activity per tissue weight was about 30% decreased
when compared with values from tumors in untreated animals (P =
.05). Clearly, in the absence of pharmacodynamic/pharmacokinetic
studies, and with no defined inhibitor “on/off” values, the implication
of reduced, but not absent, FAP activity is difficult to interpret.
Others have made similar observations [24,27], the sum of which
may suggest that reduced FAP proteolytic activity equal to or beyond
a critical threshold is sufficient to diminish tumor growth by either
lessening availability of ECM scaffolding or by reestablishing immune
intolerance somehow.
Our IHC analyses of untreated and treated tumors are contained in
Figure 6. Two representative sections are shown for each staining
procedure used for each treatment group: 1) saline control, 2) M83,
and 3) J94. FAP staining of tumor sections from untreated control
mice occurred largely in highly vascularized stromal areas, frequently
appearing parallel to the longitudinal axes of vessels. These findings
agree with our past observation that FAP production begins 4 to
6 hours after the onset of tube formation by endothelial cells (ECs)
cultured on Matrigel and points to the likelihood that FAP proteinase
activity facilitates vessel growth into ECM [10,23]. Concentrated areas
of FAP staining were apparent in the M83-treated group, but vessel
formation was reduced when compared to control sections, suggesting
that diminished “burrowing” capability of vessels into ECM reduced
the density of their usual stromal patterns. In the examples shown for
J94-treated tumors, the predilection for FAP depositions to align along
microvessels is apparent as is reduced CD31 staining in surrounding
areas, indicating less microvasculature development.
Picrosirius staining of collagen in the untreated tumor sections
showed narrow green-stained filamentous structures in more or less
parallel longitudinal arrangements. In theM83-treated group, however,
collagen was present in large accumulations of thickened fibers, which
frequently manifested a yellow to bright orange staining. These
accumulations are consistent with collagen undergoing partial cleavage
or modest degradation before extensive digestion by FAP occurs [12].
Hence, it is reasonable to speculate that collagen within M83-treated
tumors is initially cleaved by matrix metalloproteinases (MMPs), and
since FAP is inhibited byM83, further proteolysis cannot proceed, and
consequently, large derivative collagen peptides accumulate. With J94
inhibition of POP, collagen appeared unaffected and gave a
filamentous, fibrillar pattern, essentially as in control tumors.
POP is normally distributed throughout virtually all tissues,
showing some increased expression in brain, kidney, and testes [59].
The distribution of POP within cells remains unsettled, although it
is generally agreed that it is found mostly in cytosol [32]. It has been
reported within the nucleus, and while lacking structural features
consistent with membrane insertion, it is found on the external
surface of cell membranes, conceivably through lipid conjugation
[60]. IHC staining showed POP to be distributed in somewhat
irregular patterns within control tumors but perhaps less dense and
homogeneous than in tumor sections from M83- or J94-treated
Figure 5. FAP and POP identified from HCT116 mouse xenograft tissue homogenates by excision of protein bands following gel
electrophoresis, which were then digested with trypsin, analyzed by HPLC–MS/MS, and identified by MASCOT database search. The
complete amino acid sequence of each protein is shown beginning with the amino terminus. (A) Peptides that represented 28% of the
amino acid sequence deduced from the DNA sequence were identified. Amino acids in blue are peptides unique to mouse FAP as
identified in the tumor tissue, while those in red are peptides that are common to both mouse and human FAPs. (B) Peptides representing
73% of the human POP sequence were observed. Amino acids in green represent peptides unique to human POP that were identified in
the tumor tissue, while those in red are peptides that confirm the identification of POP but are common to both mouse and human forms.
(C) Pulverized tumors from three control mice and threemice treated withM83 at 100 μg/day were suspended in 2× SDS sample buffer at
equivalent mg/ml concentrations. Equal volumes of each were subjected to SDS-PAGE, transferred to nitrocellulose, and then Western
blotted with either rabbit anti-FAP or (D) goat anti-POP. The human FAP reference protein for panel C was 5 ng of the native soluble
version termed APCE (94.5 kDa), and the reference for panel D was 1.5 ng of human POP (73 kDa).
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sections doubly stained for POP and CD31 revealed more
microvessels from untreated than from the M83- or J94 inhibitor–
treated groups, the latter being consistent with overlapping
inhibition of POP and FAP by M83 and only POP inhibition by
J94 [10,49]. The decreased angiogenesis observed with inhibition of
POP can be explained by diminished cleavage and, hence, availability of
the angiogenic stimulating acetyl-SDKP tetrapeptide from selected
thymosin β4 peptides, which would be anticipated to reduce
angiogenesis [33,38,61].
The most obvious and easiest established metric in our study was
the extent of tumor growth suppression by either of our two
inhibitors, which suggested that cell death must have occurred by
necrosis, apoptosis, or both. In Figure 6, two sections of untreated
tumors stained for ssDNA showed small, somewhat indistinct areas of
staining that were irregularly distributed throughout both sections. In
contrast, M83-treated tumor sections contained large areas of
antibody staining consistent with apoptotic zones that covered on
average N40% of each field examined under low-power magnification
(differing significantly from the untreated average of 13%, P b .01).
Interestingly, sections from the J94-treated tumors showed less
extensive apoptosis of 31% per microscopic field (P = .06 vs
untreated). Diminished angiogenesis could account for cell death in
both the M83- and J94-treated tumors; however, the more extensiveapoptosis in the M83-treated group might have also resulted from
inhibition of FAP proteolytic activity necessary for degradation of
collagen or other substrates within ECM to yield products essential
for cell maintenance and survival.
Discussion
The relatively consistent findings of FAP, POP, and thymosin β4
overexpression in cancer TME has prompted efforts to determine
whether inhibition of each or selected combinations might serve as a
potential therapeutic target for tumor growth suppression
[5,6,8,10,13,15,32–34,54]. Neither FAP nor POP has a precisely
defined biologic function. FAP is believed to cleave minimally
degraded or denatured type I collagen into small peptides [12] as
ECM becomes remodeled for tumor growth. The proteolytic
function of FAP may also support angiogenesis by aiding growth of
new microvasculature into ECM [9,23,52,62–65]. POP is believed to
modulate the activities and levels of several biologic peptides b30
amino acids, most of which lack clearly established functions [66–69].
Increased amounts of POP have been noted in cell cytosol and on cell
membranes of cancers [30–32]. Tβ4, present in virtually all tissues,
undergoes partial cleavage by an unidentified proteinase to generate
fragments that POP—but not FAP—cleaves to yield several peptides,
including the N-terminal tetrapeptide, acetyl-SDKP, which promotes
angiogenesis at subnanomolar levels [33,38,61]. When acetyl-SDKP
Figure 6. IHC staining of excisedHCT116 xenografts. Tissueswere double-stained for FAP andCD31 in rowone, POP andCD31 in row three,
or ssDNA and CD31 in row four. In addition, tissueswere stainedwith picrosirius red for detection of collagen, as shown in row two. The two
leftmost columns represent stained images of untreated control tumors, the two center columns show stained tumors from M83-treated
mice, and the two rightmost columns show the stained tumor tissue from mice treated with J94. All images were at ×20 magnification.
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well as the development of fibrosis in selected tissues [37,70,71].
We selected a daily dose of M83 or J94 based on 1) the Ki for each
inhibitor, 2) inhibition of FAP and POP byM83 or J94 in tissue culture
studies [10], and 3) preliminary dose-ranging experiments in a like
xenograft cancer model. About the same extent of tumor growth
suppression was found forM83 or J94, despite J94 only inhibiting POP
(Figure 2). Gel band intensities for FAP or POP per unit weight of
tumor tissue (Figure 5C and D) from untreated or M83-treated mice
were essentially the same, suggesting that the relative amount of each
enzyme to tumor size was not changed by the inhibitor; moreover,
specific IHC staining for FAP or POP appeared unchanged in untreated
and M83- or J94-responsive tumors. The sum of these observations
contravenes the suggestion that FAP protein, even when proteolytically
inactive, promotes immune tolerance of cancer [51]. In that study,
Huang et al. proposed that tumor growth could still occur whether FAP
proteinase activity is present or not, thereby suggesting that immune
tolerance is enhanced by themere presence of FAP protein and that FAP
proteolytic activity is non-essential for tumor growth. However, in our
tumor model in immunocompromised mice, where immune tolerance
is not involved unless through some degree of T-cell leakage as a
consequence of the intricacies of large-scale commercial breeding of
nude mice, or by diminished natural killer (NK) cell function,
inhibition of FAP proteolytic activity resulted in marked tumor
suppression. Since Huang et al. [51] used xenografts composed of
carcinoma cells transfected with proteolytically inactive FAP to expressthe mutated FAP, rather than cancer-associated fibroblasts (CAFs),
proteolytically active FAP could be produced byCAFswithin host stroma
as it invades the transfected cancer cell xenografts. Others have suggested
that the stroma of cancer xenografts derives from the host [24,72], but
this is now definitively established by FAP and POP amino acid sequence
studies (Figure 5A and B) that show xenograft stroma clearly expresses
proteolytically active mouse FAP. This and the fact that reduced tumor
growth has been shown to result from decreased FAP proteolytic activity,
whether by proteinase inhibition [27,45,46] or reduced FAP expres-
sion [24], despite relatively modest changes in FAP protein levels,
supports a role for FAP proteinase function in tumor growth.
During the 28-day treatment period, tumor growth suppression
was closely similar in individual M83-treated mice (Figure 3B). Given
that 100-μg M83 treatments resulted in complete or nearly complete
disappearance of two expanding tumors by day 28, and a second
decline in tumor volume between days 24 and 28 in about half of the
tumors, the question ofwhether longer treatmentmight have resulted in
further growth suppression of tumors still apparent at 28 days is raised.
The IHC analyses of untreated and treated tumors that showed FAP
staining concentrated mainly in highly vascularized areas, and prior
observations that FAP production begins and increases withmicrovessel
growth [10,23], suggest that FAP proteolytic activity might derive from
ECs or fibroblast-related pericytes and facilitate the growth of
microvessels into ECM.
The accumulation of disorganized collagen in the M83-treated
group agrees with reports that collagen is present in excess as FAP
Figure 7. Average remaining tumor volumes after different tumor
growth suppression methods. Reported effects of four different
treatment approaches are compared with our results for M83 on
tumor growth inhibition. Growth inhibition by M83 treatment
exceeded that given by the less specific inhibitor, PT630 [24], by
the inhibitor, PT100 [51], and by shRNA knockdown of FAP
expression [53] and surpassed tumor growth reduction observed in
FAP knockout mice [24].
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in purified systems to show that type I collagen must first undergo
partial degradation before FAP can digest it further to small peptides
[12]. Tumor expansion is suggested to involve both fibroblast-derived
MMPs and FAP in ECM remodeling [23,51,62], thereby providing
the elements for a similar sequence of collagen digestion in vivo as
space is excavated for tumor growth. In M83-treated tumor
specimens, picrosirius-stained collagen appeared as large deposits of
short, thick brightly orange fluorescent fibrils that were chaotically
arranged in contrast to the narrower, more directionally organized,
needle-like green fluorescent filaments within untreated tumors. The
correlation of collagen thickness with such a staining differential has
been described before [73]. The collections of collagen fibrils in M83-
treated tumors probably represent MMP-cleaved collagen fragments
that cannot be digested further by M83-inhibited FAP [12]. Whether
such accumulations of large degraded collagen fragments participate
in localized fibrosis that might deter cancer growth, diminish invasion
of new microvasculature, or interfere with diffusion of subsequent
therapeutic agents remain challenging questions for future study [74].
The putative participation of FAP in angiogenesis remains unclear but
probably involves some pathways different from those of POP.
Whereas POP proteolytically cleaves thymosin β4 fragments to yield
the acetyl-SDKP tetrapeptide that clearly stimulates angiogenesis
[33,38,39], FAP does not make this cleavage. The overlapping
inhibition of both POP and FAP activities by M83, as also reported
with some other FAP inhibitors [75], makes assigning a specific
angiogenic function for FAP difficult; however, the synchrony with
which EC cultures express FAP [10,23] and the aforementioned POP
proteolytic activities suggest that both may participate in regulatory
processes important in microvessel organization and growth into
underlying matrix. Preliminary data obtained in our laboratory
indicate that M83 as well as J94 disrupts in vitro microvessel
formation, which agrees with and predicts our present in vivo results
that show inhibition of POP suppresses angiogenesis in synchrony
with reduced tumor growth. We also suggest, however, that M83-
induced tumor growth suppression is not due solely to diminished
acetyl-SDKP tetrapeptide production as a consequence of POP
inhibition [38–41] but also to M83 inhibition of FAP proteolytic
activity as expressed by those CAFs and pericytes necessary for
channeling of microvessels throughout the ECM [26,65].
M83-treated tumors stained for ssDNA showed large, irregular
areas of apoptosis but fewer than expected inflammatory cells.
Interestingly, gross inspection of growth-suppressed tumors showed
virtually none of the classic findings of inflammation. With J94,
apoptosis was also apparent but usually in smaller finger-like zones of
cell debris that stained positive for ssDNA and that were often
coincident with CD31-positive microvessels. In contrast, tumors
from untreated mice displayed significantly less apoptosis. These
observations suggest that impaired microvessel development due to
M83 or J94 inhibition of POP leads to hypoxia, diminished nutrient
supply, enhanced permeability, and ultimately cell death [36,38,76].
Santos et al. [24] described minimal apoptosis in tumors treated
with Glu-boroPro that may have been less impressive than what we
observed in M83- or J94-treated tumors. Whether our finding of
large areas of apoptosis is due to M83 functioning as a more specific
and sustained inhibitor than Glu-boroPro, or whether M83 has direct
apoptotic effects, was not addressed by us. Importantly, however,
others [53] have shown that knockdown of FAP expression by
shRNA caused three-fold greater apoptosis in syngeneic breast cancergrafts than in control animals, which prompts the conclusion that
diminished FAP proteolytic activity, whether by direct inhibition or
by decreasing FAP expression, causes extensive apoptosis as tumor
growth is suppressed. No gross or microscopic abnormalities, including
fibrosis, were apparent in the hearts, livers, lungs, kidneys, and spleens
ofM83- or J94-treatedmice, which suggest effective tumor targeting by
either inhibitor without apparent off-targeting effects. It might be
speculated that inhibitors of POP that are hydrophobic and enter the
cell may interfere with cellular processes that otherwise prevent fibrosis
[71], in which case, the hydrophilicity and positively charged structures
ofM83 and J94 would likely prevent cell entry [77], thereby explaining
the lack of fibrosis in our study.
In mouse models of cancer, immunologic [18] or pharmacologic
destruction of small numbers of FAP+ cells in normal skeletal muscle
and bone marrow [17,19] was associated with cachexia, anemia, and
bone toxicity reminiscent of human paraneoplastic syndromes. It is
not clear whether decreased FAP protein, or more specifically, FAP
proteinase activity, prompted these changes, or whether they were due
to loss of other specific FAP+ cellular functions. In our present study,
inhibition of both FAP and POP proteolytic activities by M83, or
POP alone by J94, resulted in greater tumor suppression (Figure 7)
than other FAP-targeting approaches such as shRNA [53], FAP-gene
disruption [24], or dipeptidyl boroPro [27,45,46,51,78] proteinase
inhibitors. Our findings suggest that FAP+ cell destruction may be
unnecessary so long as FAP and POP proteinase activities are
effectively inhibited. Having demonstrated previously that bone
marrow mesenchymal stem cells produced FAP as a constituent
membrane protein [10], and being aware that FAP is likewise present
on tissue-specific resident stem cell membranes [18,19], we were also
concerned about off-target inhibitory effects and the development of
paraneoplastic features during growth suppression of colon cancer
xenografts by FAP and POP proteinase inhibitors, but like others
[20,79,80], we observed none of the adverse effects recently reported
by the two groups [18,19]. In fact, treatment with M83 or J94 was
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lively and socially interactive with cage mates; loss of appetite, weight
loss N10%, listlessness, changes in grooming habits, hunching, or
bowel dysfunction was not seen in any mouse during the treatment
period. While not substitutive for formal toxicity studies, the
continuation of apparent good health in mice during the month of
treatment with either inhibitor suggests that neither the pseudopep-
tide “stem” of our inhibitor constructs nor the boronic acid warhead
[44,81] caused obvious adverse effects. Others have also noted a
relative absence of toxicity with in vivo use of boroPro-containing
drugs [82]. Clearly, our results and those referred to above underscore
some of the dramatic differences sometimes observed with dissimilar
therapeutic approaches.
Our results advance knowledge about two inhibitors of potential
therapeutic targets for common cancers. Neither cyclize, thereby
becoming inactive, nor inhibit DPPIV; both are easily soluble in
aqueous media, and since both inhibitors are charged and not
hydrophobic, intracellular entry and consequent POP inhibition
within the cell is highly unlikely. We conclude that combined
inhibition of FAP and POP by M83 is anti-angiogenic, causes
buildup of erratically arranged collagen fibers, and results in
widespread apoptosis within the tumor—the sum of which suppresses
colon cancer xenograft growth. Similar growth inhibition byM83 was
noted with human lung cancer xenografts, and while detailed IHC
pathologic analyses were not performed in that study, it is reasonable
to assume that results would parallel those for human colon cancer
xenografts. Inhibition of POP by J94 showed similar anti-angiogenic
effects, and despite collagen appearing unaltered, and the presence of
apoptotic patterns that differed from those yielded by M83, tumor
growth suppression still occurred (Figure 2). Further studies will be
necessary to determine if simultaneous inhibition of FAP and POP by
M83 is more effective than inhibiting either enzyme alone, and
importantly, whether each enzyme is involved in separate, unique
mechanisms that promote angiogenesis. Overall, our findings with
M83 are mostly in line with those in which FAP enzymatic activity
was putatively diminished without apparent FAP+ cell destruction.
Finally, we raise the specter of whether tumor growth suppression
might continue—even to complete disappearance—with longer
administration of M83 or J94 and without evident toxicity. Such
an assessment should also be informative as to whether M83 or J94
may be more effective (Figure 2B) over a longer treatment period.
References
[1] Connolly J, Schnitt S, Wang H, Dvorak A, and Dvorak H (2000). Principles of
Cancer Pathology. In: Bast RJ, Kufe D, Pollock R, Welchselbaum R, Holland J,
Frei E, editors. Holland-Frei Cancer Medicine; 2000.
[2] Folkman J (1990). What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst 82, 4–6.
[3] Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, and Rettig WJ
(1999). Fibroblast activation protein, a dual specificity serine protease expressed
in reactive human tumor stromal fibroblasts. J Biol Chem 274, 36505–36512.
[4] Garin-Chesa P, Old LJ, and Rettig WJ (1990). Cell surface glycoprotein of
reactive stromal fibroblasts as a potential antibody target in human epithelial
cancers. Proc Natl Acad Sci U S A 87, 7235–7239.
[5] Cheng JD, Dunbrack Jr RL, Valianou M, Rogatko A, Alpaugh RK, and
Weiner LM (2002). Promotion of tumor growth by murine fibroblast activation
protein, a serine protease, in an animal model. Cancer Res 62, 4767–4772.
[6] Puré E (2009). The road to integrative cancer therapies: emergence of a tumor-
associated fibroblast protease as a potential therapeutic target in cancer. Expert
Opin Ther Targets 13, 967–973.[7] Hayward SW (2010). Preclinical assessment of fibroblast activation protein as a
target for antitumor therapy. Future Oncol 6, 347–349.
[8] Brennen WN, Isaacs JT, and Denmeade SR (2012). Rationale behind targeting
fibroblast activation protein-expressing carcinoma-associated fibroblasts as a
novel chemotherapeutic strategy. Mol Cancer Ther 11, 257–266.
[9] Tchou J and Conejo-Garcia J (2012). Targeting the tumor stroma as a novel
treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a
stroma-centric paradigm. Adv Pharmacol 65, 45–61.
[10] Christiansen VJ, Jackson KW, Lee KN, Downs TD, and McKee PA (2013).
Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase
activities on cells common to metastatic tumor microenvironments.Neoplasia 15,
348–358.
[11] Cheng JD and Weiner LM (2003). Tumors and their microenvironments: tilling
the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of
sibrotuzumab in patients with advanced or metastatic fibroblast activation
protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin Cancer Res
9, 1590–1595.
[12] Christiansen VJ, Jackson KW, Lee KN, and McKee PA (2007). Effect of
fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen
types I, III, and IV. Arch Biochem Biophys 457, 177–186.
[13] Liu R, Li H, Liu L, Yu J, and Ren X (2012). Fibroblast activation protein: A
potential therapeutic target in cancer. Cancer Biol Ther 13, 123–129.
[14] Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, and
Cheng JD (2011). FAP-overexpressing fibroblasts produce an extracellular
matrix that enhances invasive velocity and directionality of pancreatic cancer
cells. BMC Cancer 11, 245.
[15] Jacob M, Chang L, and Pure E (2012). Fibroblast activation protein in
remodeling tissues. Curr Mol Med 12, 1220–1243.
[16] Liao D, Luo Y, Markowitz D, Xiang R, and Reisfeld RA (2009). Cancer
associated fibroblasts promote tumor growth and metastasis by modulating the
tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS
One 4, e7965.
[17] Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO,
Gopinathan A, Tuveson DA, and Fearon DT (2010). Suppression of antitumor
immunity by stromal cells expressing fibroblast activation protein-alpha. Science
330, 827–830.
[18] Tran E, ChinnasamyD, YuZ,MorganRA, Lee CC, RestifoNP, and Rosenberg SA
(2013). Immune targeting of fibroblast activation protein triggers recognition
of multipotent bone marrow stromal cells and cachexia. J Exp Med 210,
1125–1135.
[19] Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M,
Kraman M, McKenna B, and Wells RJ, et al (2013). Depletion of stromal cells
expressing fibroblast activation protein-α from skeletal muscle and bone marrow
results in cachexia and anemia. J Exp Med 210, 1137–1151.
[20] Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, WuMF, Liu H, Wang LL,
RowleyDR, and Pfizenmaier K, et al (2013). Antitumor effects of chimeric receptor
engineered human T cells directed to tumor stroma. Mol Ther 21, 1611–1620.
[21] Reisfeld RA (2013). The tumor microenvironment: a target for combination
therapy of breast cancer. Crit Rev Oncog 18, 115–133.
[22] Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM,
Roberts EW, Zhao Q, and Caballero OL, et al (2013). Targeting CXCL12 from
FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1
immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110, 20212–20217.
[23] Huang Y, Wang S, and Kelly T (2004). Seprase promotes rapid tumor growth
and increased microvessel density in a mouse model of human breast cancer.
Cancer Res 64, 2712–2716.
[24] Santos AM, Jung J, Aziz N, Kissil JL, and Puré E (2009). Targeting fibroblast
activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest
119, 3613–3625.
[25] Zimmerlin L, Donnenberg VS, and Donnenberg AD (2012). Pericytes: a
universal adult tissue stem cell? Cytometry A 81, 12–14.
[26] Jung YD, Ahmad SA, Liu W, Reinmuth N, Parikh A, Stoeltzing O, Fan F, and
Ellis LM (2002). The role of the microenvironment and intercellular cross-talk in
tumor angiogenesis. Semin Cancer Biol 12, 105–112.
[27] Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH,
Bachovchin WW, and Weiner LM (2005). Abrogation of fibroblast activation
protein enzymatic activity attenuates tumor growth.Mol Cancer Ther 4, 351–360.
[28] Sedo A, Krepela E, and Kasafirek E (1991). Dipeptidyl peptidase IV, prolyl
endopeptidase and cathepsin B activities in primary human lung tumors and lung
parenchyma. J Cancer Res Clin Oncol 117, 249–253.
Neoplasia Vol. 17, No. 1, 2015 Suppression of Tumor Growth in Mice Jackson et al. 53[29] Goossens F, De Meester I, Vanhoof G, and Scharpé S (1996). Distribution of
prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin
Chem Clin Biochem 34, 17–22.
[30] Larrinaga G, Perez I, Blanco L, Lopez JI, Andrés L, Etxezarraga C, Santaolalla F,
Zabala A, Varona A, and Irazusta J (2010). Increased prolyl endopeptidase
activity in human neoplasia. Regul Pept 163, 102–106.
[31] Myöhänen TT, Pyykkö E, Männistö PT, and Carpen O (2012). Distribution of
prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal
tumors. J Histochem Cytochem 60, 706–715.
[32] Larrinaga G, Perez I, Blanco L, Sanz B, Errarte P, Beitia M, Etxezarraga MC,
Loizate A, Gil J, and Irazusta J, et al (2014). Prolyl endopeptidase activity is
correlated with colorectal cancer prognosis. Int J Med Sci 11, 199–208.
[33] Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A, and
Wdzieczak-Bakala J (2010). Overexpression of the natural tetrapeptide acetyl-N-
ser-asp-lys-pro derived from thymosin β4 in neoplastic diseases. Ann N Y Acad Sci
1194, 53–59.
[34] Cha HJ, Jeong MJ, and Kleinman HK (2003). Role of thymosin β4 in tumor
metastasis and angiogenesis. J Natl Cancer Inst 95, 1674–1680.
[35] Nemolato S, Restivo A, Cabras T, Coni P, Zorcolo L, Orru G, Fanari M, Cau F,
Gerosa C, and Fanni D, et al (2012). Thymosin β-4 in colorectal cancer is
localized predominantly at the invasion front in tumor cells undergoing epithelial
mesenchymal transition. Cancer Biol Ther 13, 191–197.
[36] Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, Jung MH, Ock MS, and
Cha HJ (2011). Elevated expression of thymosin β4, vascular endothelial growth
factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical
cancers. Pathol Oncol Res 17, 493–502.
[37] Cavasin MA, Rhaleb NE, Yang XP, and Carretero OA (2004). Prolyl
oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Hypertension 43, 1140–1145.
[38] Myohanen TT, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R, Moreno-
Baylach MJ, Garcia-Horsman JA, and Mannisto PT (2011). Prolyl oligopepti-
dase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.
Br J Pharmacol 163, 1666–1678.
[39] Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, and Yang XP
(2004). N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and
in vivo. Am J Physiol Heart Circ Physiol 287, H2099-2105.
[40] Smart N, Rossdeutsch A, and Riley PR (2007). Thymosin β4 and angiogenesis:
modes of action and therapeutic potential. Angiogenesis 10, 229–241.
[41] Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, and Kleinman H (1999).
Thymosin beta4 enhances endothelial cell differentiation and angiogenesis.
Angiogenesis 3, 125–135.
[42] Suzuki K, Sakaguchi M, Tanaka S, Yoshimoto T, and Takaoka M (2014). Prolyl
oligopeptidase inhibition-induced growth arrest of human gastric cancer cells.
Biochem Biophys Res Commun 443, 91–96.
[43] Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, and Wallner BP (2004).
PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor
effects and augments antibody-mediated cytotoxicity via a novel immune
mechanism. Cancer Res 64, 5471–5480.
[44] Nemunaitis J, Vukelja SJ, Richards D, Cunningham C, Senzer N, Nugent J,
Duncan H, Jones B, Haltom E, and Uprichard MJ (2006). Phase I trial of PT-
100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for
solid tumor malignancy. Cancer Invest 24, 553–561.
[45] Narra K, Lee HO, Lerro A, Valvardi J, Azeez O, Jesson MI, Aziz N, Jones B, and
Cheng JD (2006). Inhibitors of the stromal protease fibroblast activation protein
attenuate tumor growth in vivo. AACR Meeting Abstracts; 2006. p. 1029.
[46] Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K,
Christiansen VJ, McKee PA, Egleston B, Cohen SJ, and Weiner LM, et al
(2007). Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast
Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther 6,
1691–1699.
[47] WalshMP,Duncan B, Larabee S, Krauss A,Davis JP, Cui Y, Kim SY,GuimondM,
Bachovchin W, and Fry TJ (2013). Val-boroPro accelerates T cell priming via
modulation of dendritic cell trafficking resulting in complete regression of
established murine tumors. PLoS One 8, e58860.
[48] Kelly T, Adams J, Bachovchin W, Barton R, Campbell S, Courts S, Kennedy C,
and Snow R (1993). Immunosuppressive boronic acid dipeptides: correlation
between conformation and activity. J Am Chem Soc 115, 12637–12638.
[49] Lee KN, Jackson KW, Christiansen VJ, Dolence EK, and McKee PA (2011).
Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-
antiplasmin. J Thromb Haemost 9, 987–996.[50] Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, and Meltzer HY
(1995). Alterations in plasma prolyl endopeptidase activity in depression, mania,
and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic
drugs. Psychiatry Res 58, 217–225.
[51] Huang Y, Simms AE, Mazur A, Wang S, León NR, Jones B, Aziz N, and Kelly T
(2011). Fibroblast activation protein-α promotes tumor growth and invasion of
breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28,
567–579.
[52] Kelly T, Huang Y, Simms AE, and Mazur A (2012). Fibroblast activation
protein-α: a key modulator of the microenvironment in multiple pathologies. Int
Rev Cell Mol Biol 297, 83–116.
[53] Cai F, Li Z, Wang C, Xian S, Xu G, Peng F, Wei Y, and Lu Y (2013). Short
hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and
improves the tumor microenvironment in a mouse model. BMB Rep 46,
252–257.
[54] Xiao Y, Chen Y, Wen J, Yan W, Zhou K, and Cai W (2012). Thymosin β4: a
potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 22,
109–116.
[55] Lee KN, Jackson KW, Terzyan S, Christiansen VJ, andMcKee PA (2009). Using
substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation
protein inhibitor design. Biochemistry 48, 5149–5158.
[56] Gorrao SS, Hemerly JP, Lima AR, Melo RL, Szeltner Z, Polgar L, Juliano MA,
and Juliano L (2007). Fluorescence resonance energy transfer (FRET) peptides
and cycloretro-inverso peptides derived from bradykinin as substrates and
inhibitors of prolyl oligopeptidase. Peptides 28, 2146–2154.
[57] Schneider CA, Rasband WS, and Eliceiri KW (2012). NIH Image to ImageJ: 25
years of image analysis. Nat Methods 9, 671–675.
[58] Van ER and Lambeir AM (2011). Structure and function relationship in prolyl
oligopeptidase. CNS Neurol Disord Drug Targets 10, 297–305.
[59] Goossens F, De MI, Vanhoof G, and Scharpé S (1992). A sensitive method for
the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 30,
235–238.
[60] Tenorio-Laranga J, Venäläinen JI, Männistö PT, and García-Horsman JA
(2008). Characterization of membrane-bound prolyl endopeptidase from brain.
FEBS J 275, 4415–4427.
[61] Liu JM, Kusinski M, Ilic V, Bignon J, Hajem N, Komorowski J, Kuzdak K,
Stepien H, and Wdzieczak-Bakala J (2008). Overexpression of the angiogenic
tetrapeptide AcSDKP in human malignant tumors. Anticancer Res 28, 2813–2817.
[62] Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, and Sloane BF
(2009). Live-cell imaging demonstrates extracellular matrix degradation in
association with active cathepsin B in caveolae of endothelial cells during tube
formation. Exp Cell Res 315, 1234–1246.
[63] Newman AC, Nakatsu MN, Chou W, Gershon PD, and Hughes CC (2011).
The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix
proteins are essential for endothelial cell lumen formation. Mol Biol Cell 22,
3791–3800.
[64] Fukumura D and Jain RK (2007). Tumor microvasculature and microenviron-
ment: targets for anti-angiogenesis and normalization. Microvasc Res 74, 72–84.
[65] Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ,
Nakagawa H, and Herlyn M (2008). The essential role of fibroblasts in esophageal
squamous cell carcinoma-induced angiogenesis. Gastroenterology 134, 1981–1993.
[66] Polgár L (2002). The prolyl oligopeptidase family. Cell Mol Life Sci 59, 349–362.
[67] García-Horsman JA, Männistö PT, and Venäläinen JI (2007). On the role of
prolyl oligopeptidase in health and disease. Neuropeptides 41, 1–24.
[68] Tenorio-Laranga J, Männistö PT, and García-Horsman JA (2011). Hunting for
peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive
peptides. CNS Neurol Disord Drug Targets 10, 319–326.
[69] Myöhänen TT, García-Horsman JA, Tenorio-Laranga J, andMännistö PT (2009).
Issues about the physiological functions of prolyl oligopeptidase based on its
discordant spatial association with substrates and inconsistencies among mRNA,
protein levels, and enzymatic activity. J Histochem Cytochem 57, 831–848.
[70] Cavasin MA, Liao TD, Yang XP, Yang JJ, and Carretero OA (2007). Decreased
endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50,
130–136.
[71] Zuo Y, Chun B, Potthoff SA, Kazi N, Brolin TJ, Orhan D, Yang HC, Ma LJ,
Kon V, and Myöhänen T, et al (2013). Thymosin β4 and its degradation product,
Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int 84, 1166–1175.
[72] Spector I, Zilberstein Y, Lavy A, Nagler A, Genin O, and Pines M (2012).
Involvement of host stroma cells and tissue fibrosis in pancreatic tumor
development in transgenic mice. PLoS One 7, e41833.
54 Suppression of Tumor Growth in Mice Jackson et al. Neoplasia Vol. 17, No. 1, 2015[73] Rich L andWhittaker P (2005). Collagen and picrosirius red staining: a polarized light
assessment of fibrillar hue and spatial distribution. Braz J Morphol Sci 22, 97–104.
[74] Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, and Jain RK (2000). Role of
extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res
60, 2497–2503.
[75] JansenK,Heirbaut L, Verkerk R, Cheng JD, Joossens J, Cos P,Maes L, Lambeir AM,
De Meester I, and Augustyns K, et al (2014). Extended structure-activity
relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-
cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem
57, 3053–3074.
[76] Jo JO, Kim SR, Bae MK, Kang YJ, OckMS, Kleinman HK, and Cha HJ (2010).
Thymosin β4 induces the expression of vascular endothelial growth factor
(VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner. Biochim
Biophys Acta 1803, 1244–1251.
[77] Cooper G (2000). Transport of small molecules. The Cell: A Molecular
Approach. Sunderland, MA: Sinauer Associates; 2000 [www.ncbi.nlm.nih.gov/
books/NBK9847/].[78] Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U,
Rettig WJ, and Schnapp A (2001). Expression of the fibroblast activation protein
during mouse embryo development. Int J Dev Biol 45, 445–447.
[79] Wang LC, Lo A, Scholler J, Sun J,Majumdar RS, Kapoor V, AntzisM, Cotner CE,
Johnson LA, and Durham AC, et al (2014). Targeting fibroblast activation protein
in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth
and augment host immunity without severe toxicity. Cancer Immunol Res 2,
154–166.
[80] Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, and Denmeade SR
(2014). Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-
activated prodrug in murine xenograft models of human cancer. Prostate 74,
1308–1319.
[81] Hall DG (2011). Boronic Acids. Wiley-VCH; 2011.
[82] Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT,
Wu W, Liu Y, Maw H, and Zhou Y, et al (2008). Dipeptide boronic acid
inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo
efficacy and safety. J Med Chem 51, 6005–6013.
